

RECONCILIATION FROM REPORTED REVENUE TO UNDERLYING REVENUE

(BN YEN)	FY2018 ^{*1} Q1	FY2019 Q1	vs. PY	
Revenue	449.8	849.1	+399.3	+ 88.8%
Shire Revenue	421.7	-		
Pro-forma Revenue	871.5	849.1	-22.4	- 2.6%
FX effects ^{*2}				+1.4pp
Divestitures ^{*3}				+0.4pp
Techpool & Multilab				+0.5pp
XIIDRA & TACHOSIL				+0.1pp
Others				-0.3pp
Underlying Revenue Growth	850.2	849.1	-1.1	- 0.8%

^{*1} FY2018 Q1 revenue is a pro-forma based, adding Shire's 3 month (April – June 2018) revenue previously reported under US GAAP has been conformed to IFRS, without material differences, excluding the oncology business which was divested in August 2018, converted to JPY using FY2018 actual rate for the period.

^{*2} FX adjustment applies constant FY2018 actual full year average rate to both years (1USD=111 yen, 1EUR=129 yen).

^{*3} Major adjustments are FY2018 Q1 revenue of former subsidiaries, Guangdong Techpool Bio-Pharma Co., Ltd., and Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda., both divested in FY2018, and FY2018 Q1 and FY2019 Q1 revenue of XIIDRA of which divestiture completed in July 2019 and TACHOSIL as Takeda agreed in May 2019 to divest this product, with completion of divestiture expected to occur within FY2019.

REPORTED AND UNDERLYING GROWTH OF LEGACY SHIRE PRODUCT/THERAPEUTIC AREA SALES

(BN YEN)	FY2018 Q1		FY2019 Q1		Underlying Growth
	Reported ^{*1}	FX	Reported	FX	
GI	159.3	+1.5	171.6	+1.9	+ 7.9%
Legacy Shire	35.3	+0.5	28.6	+0.3	- 19.4%
LIALDA	11.7	+0.1	5.6	+0.1	- 51.7%
Rare Diseases	194.3	+0.1	170.7	+4.5	- 9.9%
Rare Metabolic	49.4	(0.5)	48.9	+2.0	+ 3.9%
Rare Hematology	105.2	+0.1	89.9	+2.1	- 12.6%
ADVATE	53.7	-0.2	42.7	+1.1	- 18.1%
ADYNOVATE	13.2	+0.2	16.7	+0.1	+ 25.9%
FEIBA	21.5	-0.2	13.1	+0.5	- 36.8%
Hereditary Angioedema	39.7	+0.5	31.9	+0.4	- 19.9%
FIRAZYR	23.0	+0.3	9.0	+0.2	- 60.4%
TAKHZYRO	-	-	14.5	+0.0	—
CINRYZE	14.8	+0.2	7.3	+0.1	- 50.8%
PDT Immunology	89.1	+0.6	90.2	+1.0	+ 1.6%
Legacy Shire	84.9	+0.6	85.6	+1.0	+ 1.2%
Immunoglobulin	69.5	+0.6	68.0	+0.8	- 1.9%
Legacy Shire	66.4	+0.6	64.6	+0.8	- 2.4%
Albumin	19.6	+0.1	22.2	+0.2	+ 14.1%
Legacy Shire	18.5	+0.1	21.0	+0.2	+ 14.5%
Neuroscience	100.7	+1.4	111.9	+0.6	+ 10.1%
Legacy Shire	76.4	+1.1	83.8	+0.6	+ 8.9%
VYVANSE	60.4	+0.9	68.8	+0.4	+ 12.8%
ADDERALL XR	8.8	+0.1	5.7	-0.0	- 36.6%

^{*1} Pro-forma based Legacy Shire's product sales and therapeutic area sales which include Legacy Shire's products. FY2018 Q1 revenue is a pro-forma based, adding Shire's 3 month (April – June 2018) revenue previously reported under US GAAP has been conformed to IFRS, without material differences, excluding the oncology business which was divested in August 2018, converted to JPY using FY2018 actual rate for the period.

